This slide set outlines the extension phase of the REPLACE trial, which shows that the significant reductions in hypoglycemia obtained in patients with insulin-dependent type 2 diabetes after 6 months of flash glucose monitoring use were sustained over an additional 6 months.
Source: Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Diabetes Ther 2017; 8: 573–586
Funded by an educational grant from Abbott Diabetes Care